## MEDP: Medpace Holdings, Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 4.0% in lower entry zone (4.0-10.0%), top quartile (80th pct) cross-sectional ranking. Short-term MRS_5 (2.5%) confirms momentum alignment. Strong momentum (+3.3% 5-day acceleration). Outperforming sector by 3.5%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($557.33)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Medpace Holdings: Quiet Climb Or Topping Out? What The Numbers Really Say About MEDP**
- Source: AD HOC NEWS | 20260105T014553 | Bullish | Relevance: 100%
- Medpace Holdings (MEDP) has seen modest declines recently but remains near its 52-week high after a strong multi-month rally, prompting investors to question if it's poised for further gains or facing consolidation. Wall Street's outlook is broadly positive, with most analysts holding "Buy" or "Overweight" ratings, albeit with a focus on Mepace's continued execution and industry trends. The company's future hinges on sustained contract wins, disciplined margin management, and favorable biopharma funding conditions.

**2. Medpace Holdings: Can This Quiet Compounder Keep Beating Wall Streetâ€™s Playbook?**
- Source: AD HOC NEWS | 20260104T174631 | Bullish | Relevance: 100%
- Medpace Holdings, a clinical research organization, has shown strong stock performance, trading near record highs despite wider market volatility. The company's success is attributed to disciplined execution in managing clinical trials, particularly in complex therapeutic areas. Wall Street analysts largely maintain a "Buy" consensus, with price targets suggesting further modest upside, indicating continued confidence in Medpace's growth trajectory and operational excellence.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Barclays | $525 | $485 | +8% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Barclays | main | Underweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 4 ($0.82M) |
| Sells | 26 ($217.29M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 36.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Blackrock Inc.: 8.4% (-4.4%)
- Vanguard Group Inc: 8.1% (-4.5%)
- AQR Capital Manageme: 3.6% (+65.1%)
- Wasatch Advisors LP: 3.3% (-2.1%)
- State Street Corpora: 2.4% (-4.8%)

### Key Risks

1. Heavy insider selling: $217M sold (26 transactions in 90 days).
2. Valuation stretched: PEG 3.6x requires aggressive growth execution.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Momentum building: MRS_20 improving +3.3% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 3.56 signals overvaluation risk, limited margin of safety. Forward P/E 35.5x stretched relative to 9% growth. Quality metrics strong (ROE 74%, ROA 16%, margin 18%). Analyst sentiment positive (1 raises, avg +8%). Insider selling cluster ($217.3M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $16.5B |
| Beta | 1.44 |
| 52W Range | $250.05 - $626.25 |
| Short Interest | 6.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.56 |
| Forward P/E | 35.5 |
| Current P/E | 38.8 |
| YoY Growth | 9.2% |
| EPS Direction | RISING |

### Technicals

MRS_20 strengthening from 0.7% to 4.0% (+3.3% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 80th percentile. MRS_5 at 2.5% confirms short-term momentum alignment. AM_20 at 4.2% shows strong absolute momentum above own 20MA. Outperforming sector by 3.5pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (2.10), confirming momentum. OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 4.00% (CS: 81) | Neutral |
| RSI_14 | 60.2 | Neutral |
| MACD Histogram | 2.10 | Bullish |
| vs SMA20 | 1.042x | Above |
| vs SMA50 | 1.011x | Above |
| vs SMA200 | 1.355x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $586.83
- **Stop Loss:** $557.33 (5.0% risk)
- **Target:** $631.08 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 29
- **Position Value:** $17,018.07
- **Portfolio %:** 17.02%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-02-09 (Est: $4.21)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.57 | $3.86 | +8.1% |
| 2025Q2 | $3.00 | $3.10 | +3.5% |
| 2025Q1 | $3.07 | $3.67 | +19.6% |
| 2024Q4 | $3.12 | $3.68 | +18.1% |

---
*RULE-based L3 | 2026-01-07 09:36 | MRS_20*